Document Detail

Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.
MedLine Citation:
PMID:  20966922     Owner:  NLM     Status:  MEDLINE    
The fusion oncogene, promyelocytic leukaemia (PML)-retinoic acid receptor-α (RARA), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML-RARα for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.
Hugues de Thé; Zhu Chen
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-10-22
Journal Detail:
Title:  Nature reviews. Cancer     Volume:  10     ISSN:  1474-1768     ISO Abbreviation:  Nat. Rev. Cancer     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  2010-11-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124168     Medline TA:  Nat Rev Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  775-83     Citation Subset:  IM    
Institut National de Santé et de Recherche Médicale, Centre National de Recherche Scientifique, Institut Universitaire d'Hématologie, Université Paris-Diderot UMR 944/7212, Equipe labellisée par Ligue contre Cancer, Service de Biochimie, Hôpital St. Louis, 2 avenue C. Vellefaux, 75475 Paris, CEDEX 10, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Differentiation
Leukemia, Promyelocytic, Acute / drug therapy*,  pathology
Models, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
Next Document:  Walls around tumours - why plants do not develop cancer.